Trial Profile

A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti GD2 chimeric antigen receptor T cell therapy Bellicum Pharmaceuticals (Primary)
Indications Diffuse intrinsic pontine glioma
Focus Adverse reactions
Acronyms LEVI'S-CATCH

Most Recent Events

10 Jun 2024 Recruitment completion is expected on 1/04/2025, according to Australian New Zealand Clinical Trials Registry.
10 Jun 2024 New source identified and integrated (Australian New Zealand Clinical Trials Registry (ACTRN12622000675729))
10 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com